GSK Giving 340B Entities Refunds Again for Asthma Medicine Purchases

GSK headquarters
Senderra Rx will no longer dispense GlaxoSmithKline’s asthma drug, Nucala.
GlaxoSmithKline is sending 340B covered entities refunds for overcharges totaling $100 or more for purchases of two dosage forms of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Enforceability of State Contract Pharmacy Laws Uncertain Amid Legal Challenges

Louisiana capitol
PhRMA has asked a federal district judge to block Louisiana's 340B contract pharmacy law, Act 358, which took effect Aug. 1.
While two drug manufacturers have recently relaxed or suspended their 340B contract pharmacy restrictions as a result of state laws [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

AHA Warns of “Legal Consequences” from Proposed Cuts to Fund 340B Lump Sum Payments

American Hospital Association logo
AHA officials penned a Medical Economics op-ed on “the truth behind growth of the 340B prescription drug program.”
The lead plaintiff in the legal battle that resulted in Medicare proposing an unusual lump sum payback for hospitals’ lost [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Let For-Profit Hospitals Into 340B, Trade Association Tells Senators

Federation of American Hospitals logo
The Federation of American Hospitals has asked six U.S. senators to let for-profit hospitals join the 340B program.
Congress should let for-profit hospitals into the 340B drug pricing program as “a long overdue evolutionary step” that will advance [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Five Major Drug Makers Oppose Health Center’s Legal Challenge to 340B Patient Definition

340B patient definition case
AbbVie, BMS, Lilly, and Merck jointly asked a federal district court to dismiss a health center’s challenge to the 340B patient definition. Drug maker Janssen asked the same separately.
Drug makers AbbVie, Bristol Myers Squibb, Janssen, Lilly, and Merck asked a federal district court in South Carolina on Friday [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Medicare DSH Changes Will Cut 340B Access, Draw Legal Challenge, Say Attorneys

CMS headquarters
CMS issued the final rule to implement a $9 billion lump sum payment to 340B hospitals for previous illegal cuts between 2018 and 2021.
Changes in the ways Medicare calculates hospitals’ shares of low-income patients that were finalized in a recent payment rule will [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Industry Insights Logo

Making the Case for Your 340B Program

SPONSORED CONTENT

Are you telling your 340B story? This webinar will teach you how to track the key data points that demonstrate the value of your 340B program. You will learn how to calculate your overall savings, track patient benefits, and create an Impact Profile.

Read More »

Government Watchdog Reissues Controversial Finding on Adverse Incentives in 340B Program

GAO 340B
GAO restated its controversial 2015 finding that 340B covered entities prescribe more drugs or more expensive drugs than necessary.
The U.S. Government Accountability Office late last month restated its controversial recommendation that Congress take actions to reduce incentives for [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Hospitals Charge Average 500% of Top 20 Drug Costs, Says PhRMA-Funded Analysis

The Moran Company logo
A Moran Company study, funded by PhRMA, found 340B hospitals charge an average of 500% above acquisition costs for 20 high-cost drugs.
Hospitals charge, on average, 500% of their acquisition cost for 20 individual medicines that account for the largest share of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B INDUSTRY LEADER SPOTLIGHT

Justin Rolling, VP of National Sales, PharmaForce

Justin Rolling, PharmaForce, VP of National Sales
Justin Rolling

Q: Where did you grow up?

I grew up in rural southeast Alabama in the small town of Luverne.

Q: Where did you go to college/graduate school?

I attended Troy University for both my Bachelor’s Degree and Master’s Degree and both are in accounting. I also have my CPA license. 

Q: What are your favorites?

Food: Anything

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live